Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 23;7(4):343-348.
doi: 10.17294/2330-0698.1794. eCollection 2020 Fall.

Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer

William D Gregory  1   2 , Shahila Mehboob Christie  1 , John Shell  1 , Georges J Nahhas  3 , Maharaj Singh  4   5 , Wendy Mikkelson  6
Affiliations

Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer

William D Gregory et al. J Patient Cent Res Rev. .

Abstract

We previously reported successful classification of breast cancer versus benign tissue using the Cole relaxation frequency measured on tissue excised during breast surgery as part of a study at two urban hospitals in the U.S. Midwest. Using that health system's cancer registry, we have discovered retrospectively that outcomes for patients who participated in the initial study can be classified correctly in 3 well-differentiated categories: nonrecurrent (NR); recurrent with no metastasis (RNM); and recurrent with metastasis (RM). As Cole relaxation frequency increases, the classification moves from NR to RNM and finally to RM. Multivariate analysis showed a significant association of "time-cancer-free" for all patients in these recurrent categories, with P-values ranging between 0.0001 to 0.0047. Thus, this follow-up report shows the potential feasibility of using Cole relaxation frequency as a prognostic parameter in a larger prospective study.

Keywords: Cole relaxation frequency; bioelectrical impedance; breast cancer; prognosis; recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest William Gregory and Shahila Mehboob Christie are employed at NovaScan, Inc., and Gregory and John Shell are stockholders in the company. NovaScan has patents pending on technology related to the research reported here. Advocate Aurora Health is a stockholder in NovaScan, but Wendy Mikkelson has no financial interest in the company. The remaining authors (Maharaj Singh and Georges Nahhas) have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Likelihood regions obtained from a quadratic fit of likelihood (L) data vs normalized Cole relaxation frequency (nCRF). Three regions are identified: no recurrence (L-NR) with nCRF of <3; recurrence with no metastasis (L-RNM) with nCRF of 3–6; recurrence with metastasis (L-RM) with nCRF of >6. The standard error bars for the L-RNM region (plotted in blue) are very small compared to the L-RM region (plotted in red) due to a smaller number of data points in the L-RM region.
Figure 2
Figure 2
This plot compares exceedance averaged time-cancer-free for normalized Cole relaxation frequency (nCRF, in green) and Nottingham Prognostic Index (NPI, in red). The prognosis for time-cancer-free (years) is plotted on the vertical axis. The slope of the nCRF plot changes abruptly at two region boundaries — where L-NR changes to L-RNM and where L-RNM changes to L-RM. NPI plots do not have similar demarcations at the boundary of regions NPI-1 to NPI-2, but there is a change of slope at NPI-2 to NPI-3. The t-test for independence for these regions is displayed below the figure and shows that NPI is only a prognostic parameter for recurrence with metastasis, while nCRF distinguishes all regions, one from the other, allowing statistically significant discrimination of no recurrence (NR), recurrence with no metastasis (RNM), and recurrence with metastasis (RM).
See this image and copyright information in PMC

References

    1. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94. doi: 10.1038/nrclinonc.2017.166. - DOI - PubMed
    1. Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412–24. doi: 10.5306/wjco.v5.i3.412. - DOI - PMC - PubMed
    1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34. doi: 10.1200/JCO.2005.04.7985. - DOI - PubMed
    1. McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer (Dove Med Press) 2017;9:393–400. doi: 10.2147/BCTT.S109847. - DOI - PMC - PubMed
    1. Stein RC, Dunn JA, Bartlett JM, et al. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol Assess. 2016;20(10):xxiii–xxix. 1–201. doi: 10.3310/hta20100. - DOI - PMC - PubMed

LinkOut - more resources